We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Perform a quantitative serum anti-JCV antibody test—including index value—to support risk stratification for progressive multifocal leukoencephalopathy. For high-risk patients, consider more frequent MRI screening.
Risk of developing progressive multifocal leukoencephalopathy (PML) associated with natalizumab is increased in patients who have had previous immunosuppressant therapy.
The risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab increases after 2 years of therapy. Patients with multiple sclerosis should be informed of the risk before treatment, and again after 2 years. The risk of developing PML beyond 3...
Applications received to amend the specification of a patent under sections 27 and 75 before the court and the Office.
Spontaneous reporting on the Yellow Card portal has provided important information in the identification of PML associated with some drugs.
The way you apply to licence biological products has changed
The immunomodulatory effects of fingolimod increase the risk of progressive multifocal leukoencephalopathy and opportunistic infections.
Employment Appeal Tribunal Judgment of Mrs Justice Eady on 18 April 2024.
In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.
The monitoring requirements and discontinuation criteria for dimethyl fumarate (Tecfidera) have been strengthened following a small number of reports of progressive multifocal leukoencephalopathy (PML) in patients with mild lymphopenia. Continue to monitor lymphocyte counts and advise patients to seek urgent...
Advice and guidance on the health needs of migrant patients from Chile for healthcare practitioners.
Product Safety Report for Aliex 4-in-1 Montessori Toy presenting a serious risk of choking.
Advice and guidance on the health needs of migrant patients from Benin for healthcare practitioners.
This series collates all documents relating to Rotavirus vaccination programme for infants
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Advice and guidance on the health needs of migrant patients from Jordan for healthcare practitioners.
Employment Appeal Tribunal Judgment of Judge Tayler on 12 April 2024.
Atnahs Pharma UK Ltd has informed the MHRA that the batches of Clobazam Atnahs 5mg/5ml and 10mg/5ml Oral Suspension listed in this notification do not contain the most up to date safety information.
The Green Book has the latest information on vaccines and vaccination procedures, for vaccine preventable infectious diseases in the UK.
Advice and guidance on the health needs of migrant patients from Nepal for healthcare practitioners.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.